Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

322 articles with Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

• 

  Clinical Catch-Up: September 28-October 2

  10/5/2020

  Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.

• Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients

  10/1/2020

   Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first pa

• 

  Biopharma Update on the Novel Coronavirus: September 30

  9/30/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.

• Windtree Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

  9/29/2020

  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a Phase 2 clinical trial studying lyo lucinactant

• Windtree to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Frasier, president and chief executive officer, will present at the H.C. Wainwright 22 nd Annual Global Inve

• Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates

  8/13/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, reported financial results for the second quarter ended June 30, 2020 and provided key business updates.

• 

  BioSpace Movers & Shakers, July 24

  7/24/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• Windtree Appoints John Hamill as Chief Financial Officer

  7/20/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced John Hamill has been appointed Senior Vice President, Chief Financial Officer.

• Windtree Announces Initial European Trial Sites Activated in AEROSURF® Bridging Study and a Collaboration for a Concomitant Independent Cerebral Physiology Study

  6/24/2020

   Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that all initial European trial sites are active and enrolling or able to enroll patients into i

• Windtree to Host Company and Business Update Conference Call on June 4, 2020

  5/28/2020

  Windtree Therapeutics, Inc. announced it will host a conference call and webcast, including a slide presentation, at 10:00 AM EDT on Thursday, June 4, 2020 to provide Company and business updates, including the recently announced completion of a $23 million public offering and up listing to The Nasdaq Capital Market, as well as updates on its acute cardiovascular and pulmonary clinical programs.

• Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option

  5/22/2020

   Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the closing of its previously announced public offering of 2,758,620 units at a price to the publi

• Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market

  5/20/2020

  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per

• Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates

  5/14/2020

  Windtree Therapeutics, Inc. (OTCQB: WINTD), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2020 and provided key business updates. 

• Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome

  4/29/2020

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced it has enrolled the first patient into its AEROSURF® phase 2b bridging study in premature inf

• Windtree Therapeutics Announces Reverse Stock Split - April 28, 2020

  4/28/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced a 1-for-3 reverse stock split of its issued and outstanding common stock.

• Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress

  4/6/2020

  Windtree Therapeutics, Inc. (OTCQB: WINT), today announced the presentation of a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at the American College of Cardiology (ACC) 2020 virtual meeting

• Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates

  4/3/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, reported financial results for the fourth quarter ended December 31, 2019 and provided key business updates.

• Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®

  3/31/2020

  Windtree Therapeutics, Inc. announces it has entered into a binding term sheet (the "Term Sheet") with Lee's Pharmaceutical Holdings (HK) Ltd

• Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy

  3/24/2020

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced it is planning to study its proprietary KL4 surfactant to potentially mitigate the pulmonary effects of severe COVID-19 infection.

• Windtree Therapeutics Completes $26.4 Million Private Placement

  12/9/2019

  Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it has completed a $26.4 million private placement of common stock and warrants.